glp 1 china 💊🧬China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida®) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese
Pay in 4 interest-free payments of $7.16 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://resource.chemlinked.com.cn/baipharm/articles/chinas-glp-1-ra-market-is-fueled-by-glycemic-control-weight-loss-needs.jpg)
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://www.reuters.com/resizer/v2/5LQRQPCDJRILNKQ7VTQVRSTR3Q.jpg?auth=13383a2b0e9aa12e31d1b29d76865b04ec712ccf5deb62f28cb874a7f2aec56f&width=1920&quality=80)
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iwkIbJcrY7D8/v3/-1x-1.webp)
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://www.biospectrumasia.com/uploads/articles/screenshot_24_2_2026_12930_-27230.jpeg)























